ARV 771

Biological Activity

ARV 771 is a potent BET bromodomain PROTAC^® Degrader (DC₅₀ = < 1nM). Comprises a BRD4-binding moiety joined by a linker to a ligand for Von Hippel-Lindau (VHL) protein. Degrades BRD2/3/4 in castration-resistant prostate cancer (CRPC) cell lines. Reduces androgen receptor levels and induces apoptosis in CRPC cells in vitro. Down-regulates BRD4 and induces tumor regression in CRPC xenografts in mice. Also reduces leukemia burden in a mouse model. Induces degradation of BRD-tagged CAR (chimeric antigen receptor) in T cells. BRD4 antibody validated for Simple Western™ (automated Western) instruments and Western Blot also available: Catalog # NBP1-86640.

PROTAC^® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
   Raina et al.
   Proc.Natl.Acad.Sci.U.S.A., 2016;113:7124
2. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
   Saenz et al.
   Leukemia, 2017;31:1951
3. A chemical switch system to modulate chimeric antigen receptor T cell activity through proteolysis-targeting chimaera technology.
   Lee et al.
   ACS Synth.Biol., 2020;9:987

Product Datasheets